Emtricitabine and tenofovir disoproxil fumarate tablets are the generic version of Gilead Sciences’s Truvada tablets.
Truvada is a second-line anti-HIV drug in the nucleoside reverse transcriptase inhibitor family and is used in combination with other medications to control HIV infection.
Robert Coury, vice chairman and CEO of Mylan, said: “This product approval is yet another important step in providing access to a range of critical HIV medications to patients in developing countries. Mylan and Matrix continue to make a significant contribution to bringing down the cost of these vital treatments through the expansion of our high-quality anti-retroviral franchise.”